Efficacy and safety of neoadjuvant tislelizumab combined with chemotherapy in locally advanced non-small cell lung cancer-a retrospective cohort study.

ABSTRACT:

Background

At present, comprehensive treatment is still the main approach for locally advanced non-small cell lung cancer (NSCLC) patients, and the research of neoadjuvant tislelizumab combined with chemotherapy in patients with locally advanced NSCLC is still in progress. We conducted this research in order to investigate the efficacy and safety of neoadjuvant tislelizumab combined with chemotherapy in the treatment of locally advanced NSCLC.

Methods

From January 1, 2021, to November 30, 2022, 12 patients with locally advanced NSCLC at the Fujian Medical University Union Hospital were retrospectively analyzed. All patients received three cycles of neoadjuvant immunotherapy combined with chemotherapy before surgery. The primary endpoint was pathological complete response (pC

SUBMITTER: Chen H 

PROVIDER: S-EPMC10894398 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature